{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:50:27Z","timestamp":1790905827890,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Objective.\u00a0\u00a0This randomized, double-blind, placebo-controlled, crossover trial evaluated the pharmacodynamic effects of a single 100-mg dose of ABT-639, a peripherally active, selective T-type Cav3.2 channel blocker, with the intradermal capsaicin pain model using pregabalin 300\u2009mg as a positive control.<\/jats:p>\n                  <jats:p>Subjects.\u00a0\u00a0Healthy adult males (aged 21 to 55 years) were randomly assigned to receive single oral doses of ABT-639, pregabalin, and placebo.<\/jats:p>\n                  <jats:p>Methods.\u00a0\u00a0Serial measurements for area (cm2) of hyperalgesia, allodynia, and flare response were performed over a 20-minute period after each capsaicin injection at 1 and 4\u2009hours post-dose. Capsaicin injections were administered in different arms as determined by random assignment. Serial measurements for spontaneous pain and elicited pain were performed over a 60-minute period at 1 and 4\u2009hours post-dose using a 100-mm visual analog scale. Standard safety evaluations were performed.<\/jats:p>\n                  <jats:p>Results.\u00a0\u00a0Nineteen participants were randomized and included in the analysis. No significant differences were observed between ABT-639 and placebo in spontaneous pain, elicited pain, and areas of allodynia, hyperalgesia, and flare after intradermal capsaicin injection at 1 and 4\u2009hours post-dose. In contrast, pregabalin demonstrated significant reductions in spontaneous pain at 1 and 4\u2009hours post-dose, and elicited pain and areas of allodynia and hyperalgesia at 4\u2009hours post-dose compared with placebo. ABT-639 demonstrated acceptable safety and tolerability; somnolence and euphoric mood were the most commonly reported adverse events.<\/jats:p>\n                  <jats:p>Conclusions.\u00a0\u00a0These data indicate that a single 100-mg dose of ABT-639 had no effect on experimental pain induced by intradermal capsaicin injection.<\/jats:p>","DOI":"10.1093\/pm\/pnv068","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T16:14:23Z","timestamp":1453220063000},"page":"551-560","source":"Crossref","is-referenced-by-count":14,"title":["A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the T-Type Calcium Channel Blocker ABT-639 in an Intradermal Capsaicin Experimental Pain Model in Healthy Adults"],"prefix":"10.1093","volume":"17","author":[{"given":"Mark","family":"Wallace","sequence":"first","affiliation":[{"name":"**Division of Pain Medicine, Department of Anesthesiology, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Duan","sequence":"additional","affiliation":[{"name":"\u2020 AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"\u2020 AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Locke","sequence":"additional","affiliation":[{"name":"\u2020 AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Nothaft","sequence":"additional","affiliation":[{"name":"\u2020 AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,12,16]]},"reference":[{"key":"2025112800215172300_pnv068-B1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1254\/jphs.13R05CP","article-title":"Ttype calcium channels: Functional regulation and implication in pain signaling","volume":"122","author":"Sekiguchi","year":"2013","journal-title":"J Pharmacol Sci"},{"key":"2025112800215172300_pnv068-B2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.emboj.7600515","article-title":"Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception","volume":"24","author":"Bourinet","year":"2005","journal-title":"Embo J"},{"key":"2025112800215172300_pnv068-B3","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1124\/mol.111.073205","article-title":"TTA-P2 is a potent and selective blocker of T-type calcium channels in rat sensory neurons and a novel antinociceptive agent","volume":"80","author":"Choe","year":"2011","journal-title":"Mol Pharmacol"},{"key":"2025112800215172300_pnv068-B4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pain.2009.06.012","article-title":"In vivo silencing of the Ca(V)3.2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathy","volume":"145","author":"Messinger","year":"2009","journal-title":"Pain"},{"key":"2025112800215172300_pnv068-B5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1476-5381.2012.02060.x","article-title":"Involvement of the endogenous hydrogen sulfide\/Ca(v) 3.2 T-type Ca2+ channel pathway in cystitis-related bladder pain in mice","volume":"167","author":"Matsunami","year":"2012","journal-title":"Br J Pharmacol"},{"key":"2025112800215172300_pnv068-B6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.neuroscience.2011.05.004","article-title":"Inhibition of T-type calcium channels and hydrogen sulfide-forming enzyme reverses paclitaxel-evoked neuropathic hyperalgesia in rats","volume":"188","author":"Okubo","year":"2011","journal-title":"Neuroscience"},{"key":"2025112800215172300_pnv068-B7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pain.2010.04.022","article-title":"Upregulation of Ca(v)3.2 T-type calcium channels targeted by endogenous hydrogen sulfide contributes to maintenance of neuropathic pain","volume":"150","author":"Takahashi","year":"2010","journal-title":"Pain"},{"key":"2025112800215172300_pnv068-B8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1254\/jphs.12086SC","article-title":"Colonic hydrogen sulfide-induced visceral pain and referred hyperalgesia involve activation of both Ca(v)3.2 and TRPA1 channels in mice","volume":"119","author":"Tsubota-Matsunami","year":"2012","journal-title":"J Pharmacol Sci"},{"key":"2025112800215172300_pnv068-B9","doi-asserted-by":"crossref","first-page":"10360","DOI":"10.1523\/JNEUROSCI.1041-10.2010","article-title":"Ca(v)3.2 T-type Ca2+ channel-dependent activation of ERK in paraventricular thalamus modulates acid-induced chronic muscle pain","volume":"30","author":"Chen","year":"2010","journal-title":"J Neurosci"},{"key":"2025112800215172300_pnv068-B10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1601-183X.2006.00268.x","article-title":"Attenuated pain responses in mice lacking Ca(V)3.2 T-type channels","volume":"6","author":"Choi","year":"2007","journal-title":"Genes Brain Behav"},{"key":"2025112800215172300_pnv068-B11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.pain.2012.10.023","article-title":"State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects","volume":"154","author":"Francois","year":"2013","journal-title":"Pain"},{"key":"2025112800215172300_pnv068-B12","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.pain.2014.01.015","article-title":"Ca(v)3.2 calcium channels: The key protagonist in the supraspinal effect of paracetamol","volume":"155","author":"Kerckhove","year":"2014","journal-title":"Pain"},{"key":"2025112800215172300_pnv068-B13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1476-5381.2011.01256.x","article-title":"Ttype voltage-gated calcium channels as targets for the development of novel pain therapies","volume":"163","author":"Todorovic","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2025112800215172300_pnv068-B14","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bcp.2014.03.015","article-title":"A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats","volume":"89","author":"Jarvis","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"2025112800215172300_pnv068-B15","volume-title":"A Peripherally Acting, Selective T-type Calcium Channel Blocker, ABT-639, Effectively Reduces Nociceptive and Neuropathic Pain in Rats","author":"Jarvis","year":"2013"},{"key":"2025112800215172300_pnv068-B16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1208\/s12248-015-9725-9","article-title":"Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers","volume":"17","author":"An","year":"2015","journal-title":"AAPSJ"},{"key":"2025112800215172300_pnv068-B17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1124\/pr.111.005447","article-title":"Human experimental pain models for assessing the therapeutic efficacy of analgesic drugs","volume":"64","author":"Olesen","year":"2012","journal-title":"Pharmacol Rev"},{"key":"2025112800215172300_pnv068-B18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00424-005-1457-8","article-title":"Structure and function of TRPV1","volume":"451","author":"Tominaga","year":"2005","journal-title":"Pflugers Arch"},{"key":"2025112800215172300_pnv068-B19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1113\/jphysiol.1992.sp019068","article-title":"Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin","volume":"448","author":"LaMotte","year":"1992","journal-title":"J Physiol"},{"key":"2025112800215172300_pnv068-B20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jpain.2008.05.013","article-title":"Effect of morphine and pregabalin compared with diphenhydramine hydrochloride and placebo on hyperalgesia and allodynia induced by intradermal capsaicin in healthy male subjects","volume":"9","author":"Wang","year":"2008","journal-title":"J Pain"},{"key":"2025112800215172300_pnv068-B21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00002508-200211000-00005","article-title":"Postdelivery of alfentanil and ketamine has no effect on intradermal capsaicin-induced pain and hyperalgesia","volume":"18","author":"Wallace","year":"2002","journal-title":"Clin J Pain"},{"key":"2025112800215172300_pnv068-B22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/oxfordjournals.bja.a013396","article-title":"Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans","volume":"84","author":"Gottrup","year":"2000","journal-title":"Br J Anaesth"},{"key":"2025112800215172300_pnv068-B23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jpain.2013.08.011","article-title":"Determination of the effective dose of pregabalin on human experimental pain using the sequential up-down method","volume":"15","author":"Wong","year":"2014","journal-title":"J Pain"},{"key":"2025112800215172300_pnv068-B24","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/00000542-200412000-00021","article-title":"Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia","volume":"101","author":"Gottrup","year":"2004","journal-title":"Anesthesiology"},{"key":"2025112800215172300_pnv068-B25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.anes.0000286986.92475.b7","article-title":"Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers","volume":"107","author":"Wallace","year":"2007","journal-title":"Anesthesiology"},{"key":"2025112800215172300_pnv068-B26","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/0091270009352087","article-title":"Clinical pharmacokinetics of pregabalin in healthy volunteers","volume":"50","author":"Bockbrader","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2025112800215172300_pnv068-B27","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/00000542-199706000-00008","article-title":"Alfentanil, but not amitriptyline, reduces pain, hyperalgesia, and allodynia from intradermal injection of capsaicin in humans","volume":"86","author":"Eisenach","year":"1997","journal-title":"Anesthesiology"},{"key":"2025112800215172300_pnv068-B28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1213\/00000539-200210000-00034","article-title":"The effect of chronic oral desipramine on capsaicin-induced allodynia and hyperalgesia: A double-blinded, placebo-controlled, crossover study","volume":"95","author":"Wallace","year":"2002","journal-title":"Anesth Analg"},{"key":"2025112800215172300_pnv068-B29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0091270002042001008","article-title":"Concentration-effect relationships for intravenous alfentanil and ketamine infusions in human volunteers: Effects on acute thresholds and capsaicin-evoked hyperpathia","volume":"42","author":"Wallace","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"2025112800215172300_pnv068-B30","doi-asserted-by":"crossref","first-page":"7228","DOI":"10.1073\/pnas.86.18.7228","article-title":"Ttype calcium channels mediate the transition between tonic and phasic firing in thalamic neurons","volume":"86","author":"Suzuki","year":"1989","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/17\/3\/551\/65581232\/painmedicine_17_3_551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/17\/3\/551\/65581232\/painmedicine_17_3_551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:22:02Z","timestamp":1764307322000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/17\/3\/551\/1889238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,16]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,12,16]]},"published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnv068","relation":{},"ISSN":["1526-4637","1526-2375"],"issn-type":[{"value":"1526-4637","type":"electronic"},{"value":"1526-2375","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,3]]},"published":{"date-parts":[[2015,12,16]]}}}